Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines (Hepatology International, (2021), 15, 6, (1421-1430), 10.1007/s12072-021-10263-x)

Wei Teng, Ting Tsung Chang, Hwai I. Yang, Cheng Yuan Peng, Chien Wei Su, Tung Hung Su, Tsung Hui Hu, Ming Lung Yu, Hung Chih Yang, Jaw Ching Wu

Research output: Contribution to journalComment/debatepeer-review

Abstract

Authors would like to add below funding information to their publication. This study was supported by funding from Ministry of Science and Technology (National Science and Technology Council) (104-2314-B-182A-048-MY3; 110-2314-B-A49A-505; 110-2314-B-075-010-MY3), VGHUST Joint Research Program, Tsou Foundation (VGHUST110-G7-3-3), VGHTPE Research Program (V107C-161, V108C-059 and V109C-049), Ministry of Health and Welfare (MOHW107-TDU-B-211-114019; 108-TDU-B-211-124019; 109-TDU-B-211-134019; 110-TDU-B-211-144019) and Cancer Progression Research Center, National Yang-Ming University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education. The original article has been corrected.

Original languageEnglish
JournalHepatology International
DOIs
Publication statusAccepted/In press - 2024

All Science Journal Classification (ASJC) codes

  • Hepatology

Fingerprint

Dive into the research topics of 'Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines (Hepatology International, (2021), 15, 6, (1421-1430), 10.1007/s12072-021-10263-x)'. Together they form a unique fingerprint.

Cite this